Dravet Syndrome Pipeline Insight
DelveInsight’s, “Dravet Syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dravet Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dravet Syndrome Understanding
Dravet Syndrome: Overview
Dravet syndrome, previously called severe myoclonic epilepsy of infancy (SMEI), is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe. Dravet syndrome has an estimated incidence rate of 1:15,700 individuals, 80% of whom have a mutation in their SCN1A gene. Dravet syndrome is diagnosed based on the results of a clinical exam looking for specific symptoms that have been previously seen in this condition. Genetic testing can also be helpful. Treatment involves finding the best combination of medicines to treat seizures and prevent seizure emergencies. Dietary therapy and vagus nerve stimulation can also be helpful. FDA approved medications for the treatment of Dravet syndrome include epidiolex, stiripentol, and fenfluramine.
"Dravet Syndrome - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dravet Syndrome pipeline landscape is provided which includes the disease overview and Dravet Syndrome treatment guidelines. The assessment part of the report embraces, in depth Dravet Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dravet Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Dravet Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Dravet Syndrome.
Dravet Syndrome Emerging Drugs Chapters
This segment of the Dravet Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dravet Syndrome Emerging Drugs
Soticlestat is a potent, highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). In March 2021, Takeda Pharmaceutical Company and Ovid Therapeutics announced that Takeda has entered into an exclusive agreement under which Takeda secured global rights at closing from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The drug is in Phase III clinical studies for the treatment of Dravet syndrome.
STK-001: Stoke Therapeutics
STK-001 is an antisense oligonucleotide that increases levels of SCN1a mRNA in the cell resulting in increased NaV1.1 protein production. The drug is in Phase II clinical studies for the treatment of Dravet Syndrome. STK-001 had granted orphan drug designation by the US FDA for Dravet syndrome treatment.
Further product details are provided in the report……..
Dravet Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Dravet Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dravet Syndrome
There are approx. 15+ key companies which are developing the therapies for Dravet Syndrome. The companies which have their Dravet Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Takeda.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Dravet Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Dravet Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dravet Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
- The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dravet Syndrome drugs.
Dravet Syndrome Report Insights
- Dravet Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Dravet Syndrome Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dravet Syndrome drugs?
- How many Dravet Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dravet Syndrome?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dravet Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dravet Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?